Sterne Agee Starts Endo Pharmaceuticals (ENDP) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Endo Int'l (ENDP) Unit Receives FDA Warning Letter Tied to Form 483 Notice
April 16, 2014 8:25 AM EDTAs previously reported in Endo Health Solutions Inc.s Form 10-K filed with the SEC on March 3, 2014, in February 2014, the United States Food and Drug Administration (the FDA) conducted an inspection of the Minnetonka, Minnesota facility of American Medical Systems, Inc. (AMS), a subsidiary of Endo International plc (Nasdaq: ENDP). Following such inspection, the FDA issued three observations on a Form 483 Notice of Inspectional Observations dated February 24, 2014 (the Form 483 Notice). These observations, previously self-identified by AMS, were being addressed through a corrective action plan which AMS originally expected to complete beyond 2015.
AMS provided the FDA an... More
